Valid Gahramanov

The paper shows that cancer cells develop resistance to doxorubicin by accumulating mutations at Top2 cleavage sites, which prevent DNA damage and promote adaptation.

This paper develops a mutation-independent liquid biopsy method using DNA methylation to monitor high-risk neuroblastoma through blood plasma-derived cfDNA.

The paper shows that cancer cells generate non-random, high-frequency mutations during drug adaptation, enriched near transcription factor binding sites.